Unmet clinical need in autoimmune liver diseases

Journal of Hepatology

Volumn 62, Issue 1, 2016, Pages 208-218

  Dyson, Jessica K ^a   Webb, Gwilym ^b   Hirschfield, Gideon M ^b,c   Lohse, Ansgar ^d   Beuers, Ulrich ^e   Lindor, Keith ^f   Jones, David E J ^a,c,g  

^a FREEMAN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UK PBC Research Consortium   (United Kingdom)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^e ACADEMIC MEDICAL CENTER   (Netherlands)

^f ARIZONA STATE UNIVERSITY   (United States)

^g NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

Autoimmune hepatitis; Autoimmune liver diseases; IgG4 disease; Primary biliary cirrhosis; Primary sclerosing cholangitis; Stratified care delivery; Unmet clinical need

Indexed keywords

BUDESONIDE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; FIBRIC ACID DERIVATIVE; OBETICHOLIC ACID; PREDNISOLONE; STEROID; URSODEOXYCHOLIC ACID;

ADULT; AUTOIMMUNE LIVER DISEASE; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEALTH CARE DELIVERY; HEALTH CARE NEED; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN G4 RELATED DISEASE; PROGNOSIS; QUALITY OF LIFE; RECURRENT DISEASE; REVIEW; STUDY DESIGN; TOTAL QUALITY MANAGEMENT; TREATMENT INDICATION; AUTOIMMUNE DISEASES; AUTOIMMUNITY; DISEASE MANAGEMENT; IMMUNOLOGY; LIVER DISEASES; PATHOLOGY;

AUTOIMMUNE DISEASES; AUTOIMMUNITY; DISEASE MANAGEMENT; HUMANS; LIVER DISEASES; PROGNOSIS;

EID: 84918787307     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2014.09.010     Document Type: Review

References (107)

1. J.V. Metcalf, H.C. Mitchinson, J.M. Palmer, D.E.J. Jones, M.F. Bassendine, and O.F.W. James Natural history of early primary biliary cirrhosis Lancet 348 1996 1399 1402
2. J.M. Turchany, R. Uibo, T. Kivik, J. Van de Water, T. Prindiville, and R.L. Coppel A study of antimitochondrial antibodies in a random population in Estonia Am J Gastroenterol 92 1997 124 126
3. M. Shibata, Y. Onozuka, T. Morizane, H. Koizumi, N. Kawaguchi, and H. Miyakawa Prevalence of antimitochondrial antibody in Japanese corporate workers in Kanagawa prefecture J Gastroenterol 39 2004 255 259
4. L.M. Cunha, P.L. Bittencourt, C.P. Abrantes-Lemos, A. Moreira, D. Almeida, and R. Parana Prevalence of non-organ-specific autoantibodies in a rural community from northeastern Brazil: a population-based study Hum Immunol 73 2012 70 74
5. O. Chazouilleres, D. Wendum, L. Serfaty, O. Rosmorduc, and R. Poupon Long term outcome and response to therapy of primary biliary cirrhosis-Autoimmune hepatitic overlap syndrome J Hepatol 44 2006 400 406
6. G. Gregorio, B. Portmann, J. Karani, P. Harrison, P. Donaldson, and D. Vergani Autoimmune hepatitis/sclerosing cholangitis overlap syndrome in childhood: a 16 year prospective study Hepatology 33 2001 544 553
7. K.M. Boberg, R.W. Chapman, G.M. Hirschfield, A.W. Lohse, M.P. Manns, and E. Schrumpf Overlap syndromes: the International Autoimmune Hepatitis Group (IAIHG) position statement on a controversial issue J Hepatol 54 2011 374 385
8. A.J. Czaja, M.P. Manns, I.G. McFarlane, and J.H. Hoofnagle Autoimmune hepatitis: the investigational and clinical challenges Hepatology 31 2000 1194 1200
9. A.J. Czaja Autoimmune liver disease Curr Opin Gastroenterol 25 2009 215 222
10. F. Alvarez, P.A. Berg, F.B. Bianchi, L. Bianchi, A.K. Burroughs, and E.L. Cancado International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis J Hepatol 31 1999 929 938
11. A.J. Czaja, and H.A. Carpenter Autoimmune hepatitis with incidental histologic features of bile duct injury Hepatology 34 2001 659 665
12. A.J. Czaja, P. Muratori, L. Muratori, H.A. Carpenter, and F.B. Bianchi Diagnostic and therapeutic implications of bile duct injury in autoimmune hepatitis Liver Int 24 2004 322 329
13. R.H. Wiesner, N.F. LaRusso, J. Ludwig, and E.R. Dickson Comparison of the clinicopathologic features of primary sclerosing cholangitis and primary biliary cirrhosis Gastroenterology 88 1985 108 114
14. J. Ludwig, R.L. MacCarty, N.F. LaRusso, R.A. Krom, and R.H. Wiesner Intrahepatic cholangiectases and large-duct obliteration in primary sclerosing cholangitis Hepatology 6 1986 560 568
15. K.M. Boberg, O. Fausa, T. Haaland, E. Holter, O.J. Mellbye, and A. Spurkland Features of autoimmune hepatitis in primary sclerosing cholangitis: an evaluation of 114 primary sclerosing cholangitis patients according to a scoring system for the diagnosis of autoimmune hepatitis Hepatology 23 1996 1369 1376
16. M. Carbone, G. Mells, G. Pells, M.F. Dawas, J.L. Newton, and M. Heneghan Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid Gastorenterology 144 2013 560 569
17. S. Al-Mamari, J. Djordjevic, J. Halliday, and R. Chapman Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitis J Hepatol 58 2012 329 334
18. U. Broome, R. Lofberg, B. Veress, and L.S. Eriksson Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential Hepatology 22 1997 1404 1408
19. N. Razumilava, G.J. Gores, and K.D. Lindor Cancer surveillance in patients with primary sclerosing cholangitis Hepatology 54 2011 1842 1852
20. J. Le Pendu, S. Marionneau, A. Cailleau-Thomas, J. Rocher, B. Le Moullac-Vaidye, and M. Clement ABH and Lewis histo-blood group antigens in cancer APMIS 109 2001 9 31
21. E.M. Vestergaard, H.O. Hein, H. Meyer, N. Grunnet, J. Jorgensen, and H. Wolf Reference values and biological variation for tumor marker CA 19-9 in serum for different Lewis and secretor genotypes and evaluation of secretor and Lewis genotyping in a Caucasian population Clin Chem 45 1999 54 61
22. M.A. Tempero, E. Uchida, H. Takasaki, D.A. Burnett, Z. Steplewski, and P.M. Pour Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer Cancer Res 47 1987 5501 5503
23. T.F. Orntoft, E.M. Vestergaard, E. Holmes, J.S. Jakobsen, N. Grunnet, and M. Mortensen Influence of Lewis alpha1-3/4-L-fucosyltransferase (FUT3) gene mutations on enzyme activity, erythrocyte phenotyping, and circulating tumor marker sialyl-Lewis a levels J Biol Chem 271 1996 32260 32268
24. S.L. Ong, A. Sachdeva, G. Garcea, G. Gravante, M.S. Metcalfe, and D.M. Lloyd Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration Dig Dis Sci 53 2008 3213 3217
25. D.V. Mann, R. Edwards, S. Ho, W.Y. Lau, and G. Glazer Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice Eur J Surg Oncol 26 2000 474 479
26. J. Metzger, A.A. Negm, R.R. Plentz, T.J. Weismuller, J. Wedemeyer, and T.H. Karlsen Urine proteomic analysis differentiates cholangiocarcinoma from primary sclerosing cholangitis and other benign biliary disorders Gut 62 2013 122 130
27. E.G. Barr Fritcher, B.R. Kipp, J.S. Voss, A.C. Clayton, K.D. Lindor, and K.C. Halling Primary sclerosing cholangitis patients with serial polysomy fluorescence in situ hybridization results are at increased risk of cholangiocarcinoma Am J Gastroenterol 106 2011 2023 2028
28. U. Navaneethan, N.G. Gutierrez, P.G. Venkatesh, R. Jegadeesan, R. Zhang, and S. Jang Lipidomic profiling of bile in distinguishing benign from malignant biliary strictures: a single-blinded pilot study Am J Gastroenterol 109 2014 895 902
29. A. Czaja The management of autoimmune hepatitis beyond consensus guidelines Aliment Pharmacol Ther 38 2013 343 364
30. H. Hamano, S. Kawa, A. Horiuchi, H. Unno, N. Furuya, and T. Akamatsu High serum IgG4 concentrations in patients with sclerosing pancreatitis N Engl J Med 344 2001 732 738
31. V. Deshpande, N.I. Sainani, R.T. Chung, D.S. Pratt, G. Mentha, and L. Rubbia-Brandt IgG4-Associated cholangitis: a comparative histological and immunophenotypic study with primary sclerosing cholangitis on liver biopsy material Mod Pathol 22 2009 1287 1295
32. J.H.Z.Y. Stone, and V. Deshpande IgG4-related disease N Engl J Med 366 2012 539 551
33. V. Deshpande, Y. Zen, J.K. Chan, E.E. Yi, Y. Sato, and T. Yoshino Consensus statement on the pathology of IgG4-related disease Mod Pathol 25 2012 1181 1192
34. G. Webster, S. Pereira, and R. Chapman Autoimmune pancreatitis/IgG4-Associated cholangitis and primary sclerosing cholangitis-overlapping or separate diseases J Hepatol 51 2009 398 402
35. K. Boonstra, E.L. Culver, L.M. de Buy Wenniger, M.J. van Heerde, K.J. van Erpecum, and A.C. Poen Serum immunoglobulin G4 and immunoglobulin G1 for distinguishing immunoglobulin G4-Associated cholangitis from primary sclerosing cholangitis Hepatology 59 2014 1954 1963
36. L.J. Maillette de Buy Wenniger, M.E. Doorenspleet, P.L. Klarenbeek, J. Verheij, F. Baas, and R.P. Elferink Immunoglobulin G4+ clones identified by next-generation sequencing dominate the B cell receptor repertoire in immunoglobulin G4 associated cholangitis Hepatology 57 2013 2390 2398
37. P.J. Trivedi, and G.M. Hirschfield Treatment of autoimmune liver disease: current and future therapeutic options Ther Adv Chronic Dis 4 2013 119 141
38. T. Kumagi, M. Guindi, S.E. Fisacher, T. Arenovich, R. Abdalian, and C. Coltescu Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis Am J Gastroenterol 105 2010 2186 2194
39. C. Corpechot, F. Carrat, A. Bahr, Y. Chretien, R.E. Poupon, and R. Poupon The effect of ursodeoxycholic acid therapy on the natural history of primary biliary cirrhosis Gastroenterology 128 2005 297 303
40. A. Pares, L. Caballeria, and J. Rodes Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid Gastroenterology 130 2006 715 720
41. E.M.M. Kuiper, B.E. Hansen, R.A. De Vries, J.W. Den Ouden-Muller, T.J.M. Van Ditzhuijsen, and E.B. Haagsma Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid Gastroenterology 136 2009 1281 1287
42. C. Corpechot, L. Abenavoli, N. Rabahi, Y. Chretien, T. Andreani, and C. Johanet Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis Hepatology 48 2008 871 877
43. F. Nevens, P. Andreone, G. Mazzella, S. Strasser, C. Bowlus, and P. Invernizzi The first primary biliary cirrhosis (PBC) phase 3 trial in two decades-An international study of the FXR agonist Obeticholic Acid J Hepatol 2014 S525 S526
44. C. Levy, J.A. Peter, D.R. Nelson, J. Keach, J. Petz, and R. Cabrera Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid Aliment Pharmacol Ther 33 2011 235 242
45. K. Kowdley, V. Luketic, D. Jones, R. Chapman, A. Burroughs, and G. Hirschfield The first new monotherapy therapeutic PBC study in a decade? An international study evaluating the farnesoid X receptor agonist obeticholic acid in PBC Hepatology 54 2011 416A 417A
46. S. Iwasaki, K. Tsuda, H. Ueta, R. Aono, M. Ono, and T. Saibara Bezafibrate may have a beneficial effect in pre-cirrhotic primary biliary cirrhosis Hepatol Res 16 1999 12 18
47. K. Yano, H. Kato, S. Morita, and R. Furukawa Long-term administration of bezafibrate on primary biliary cirrhosis Acta Hepatol Jpn 43 2002 115 120
48. K. Yano, H. Kato, S. Morita, O. Takahara, H. Ishibashi, and R. Furukawa Is bezafibrate histologically effective for primary biliary cirrhosis Am J Gastroenterol 97 2002 1075 1077
49. P. Angulo, R.A. Jorgensen, J.C. Keach, E.R. Dickson, C. Smith, and K.D. Lindor Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid Hepatology 31 2000 318 323
50. H. Rautiainen, P. Karkkainen, A.L. Karvonen, H. Nurmi, P. Pikkarainen, and H. Nuutinen Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial Hepatology 41 2005 747 752
51. M. Leuschner, K.P. Maier, J. Schlichting, S. Strahl, G. Herrmann, and H.H. Dahm Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial Gastroenterology 117 1999 918 925
52. U. Beuers, S. Hohenester, L.J. de Buy Wenniger, A.E. Kremer, P.L. Jansen, and R.P. Elferink The biliary HCO(3)(-) umbrella: a unifying hypothesis on pathogenetic and therapeutic aspects of fibrosing cholangiopathies Hepatology 52 2010 1489 1496
53. R.P. Myers, M.G. Swain, S.S. Lee, A.A.M. Shaheen, and K.W. Burak B-cell depletion with Rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid Am J Gastroenterol 108 2014 933 941
54. G.M. Hirschfield, X. Liu, C. Xu, Y. Lu, G. Xie, and Y. Lu Primary biliary cirrhosis associated with HLA, IL12A, and IL12RB2 variants N Engl J Med 360 2009 2544 2555
55. G.F. Mells, J.A.B. Floyd, K.I. Morley, H.J. Cordell, C.S. Franklin, and S.-Y. Shin Genome-wide association study identifies 13 additional susceptibility loci for primary biliary cirrhosis Nat Genet 43 2011 329 332
56. R.W. Chapman High-dose ursodeoxycholic acid in the treatment of primary sclerosing cholangitis: throwing the urso out with the bathwater? Hepatology 50 2009 671 673
57. E. Wunsch, J. Trottier, M. Milkiewicz, J. Raszeja-Wyszomirska, G.M. Hirschfield, and O. Barbier Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis Hepatology 60 3 2014 931 940
58. J.H. Tabibian, and K.D. Lindor Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?) Hepatology 60 2014 785 788
59. K. Lindor, K. Kowdley, V. Luketic, M. Harrison, T. McCashland, and Aea Befeler High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis Hepatology 50 2009 808 814
60. D. Gotthardt, G. Rudolph, P. Kloters-Plachky, H. Kulaksiz, and A. Stiehl Endoscopic dilation of dominant stenoses in primary sclerosing cholangitis: outcome after long-term-treatment Gastrointest Endosc 71 2010 527 534
61. A. Ghazale, and S.T. Chari Optimising corticosteroid treatment for autoimmune pancreatitis Gut 56 2007 1650 1652
62. B. Hoereldt, E. McFarlane, A. Dube, P. Basumani, M. Karajeh, and M.J. Campbell Long-term outcomes of patients with autoimmune hepatitis managed at a non-transplant center Gastroenterology 140 2011 1980 1989
63. S. Sockalingam, D. Blank, N. Abdelhamid, S.E. Abbey, and G.M. Hirschfield Identifying opportunities to improve management of autoimmune hepatitis: evaluation of drug adherence and psychosocial factors J Hepatol 57 2012 1299 1304
64. M.P. Manns, M. Woynarowski, W. Kreisel, Y. Lurie, C. Rust, and E. Zuckerman Budesonide induces remission more effectively than prednisone in a controlled trial of patients with autoimmune hepatitis Gastroenterology 139 2010 1198 1206
65. A. Dhirapong, A. Lleo, G.-X. Yang, K. Tsuneyama, R. Dunn, and M. Kehry B-cell depletion therapy exacerbates murine primary biliary cirrhosis Hepatology 53 2011 527 535
66. M. Tsuda, Y. Moritoki, Z.-X. Lian, W. Zhang, K. Yoshida, and K. Wakabayashi Biochemical and immunologic effects of Rituximab in patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid Hepatology 55 2012 512 521
67. D.E.J. Jones Pathogenesis of primary biliary cirrhosis Gut 56 2007 1615 1624
68. M. Carbone, and J. Neuberger Liver transplantation in PBC and PSC: indications and disease recurrence Clin Res Hepatol Gastroenterol 35 2011 446 454
69. R.F. Liermann Garcia, C. Evangalista Garcia, P. McMaster, and J. Neuberger Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single centre Hepatology 33 2001 22 27
70. M. Carbone, and J. Neuberger Liver transplantation in PBC and PSC: indications and disease recurrence Clin Res Hepatol Gastroenterol 34 2011 46 54
71. F. Mendes, C.A. Couto, and C. Levy Recurrent and de novo autoimmune liver diseases Clin Liver Dis 15 2011 859 878
72. D. Tripathi, and J. Neuberger Autoimmune hepatitis and liver transplantation: indications, results, and management of recurrent disease Semin Liver Dis 29 2009 286 289
73. D.E. Jones, F.E. Watt, J.V. Metcalf, M.F. Bassendine, and O.F. James Familial primary biliary cirrhosis reassessed: a geographically-based population study J Hepatol 30 1999 402 407
74. K.N. Lazaridis, B.D. Juran, G.M. Boe, J.P. Slusser, M. de Andrade, and H.A. Homberger Increased prevalence of anti-mitochondrial antibodies in first-degree relatives of patients with primary biliary cirrhosis Hepatology 46 2007 785 792
75. M.I. Prince, A. Chetwynd, P. Diggle, M. Jarner, J.V. Metcalf, and O.F.W. James The geographical distribution of primary biliary cirrhosis in a well-defined cohort Hepatology 34 2001 1083 1088
76. A. Ala, C.M. Stanca, M. Bu-Ghanim, I. Ahmado, A.D. Branch, and T.D. Schiano Increased prevalence of primary biliary cirrhosis near Superfund waste sites Hepatology 43 2006 525 531
77. C. Corpechot, Y. Chretien, O. Chazouilleres, and R. Poupon Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis J Hepatol 53 2010 162 169
78. C. Corpechot, F. Gaouar, Y. Chretien, C. Johanet, O. Chazouilleres, and R. Poupon Smoking as an independent risk factor of liver fibrosis in primary biliary cirrhosis J Hepatol 56 2012 218 224
79. C.O. Zein, K. Beatty, A.B. Post, L. Logan, S. Debanne, and A.J. McCullough Smoking and increased severity of hepatic fibrosis in primary biliary cirrhosis: a cross validated retrospective assessment Hepatology 44 2006 1564 1571
80. M.E. Gershwin, C. Selmi, H.J. Worman, E.B. Gold, M. Watnik, and J. Utts Risk factors and comorbidities in primary biliary cirrhosis: a controlled interview-based study of 1032 patients Hepatology 42 2005 1194 1202
81. F.K. Varyani, J. West, and T.R. Card An increased risk of urinary tract infection precedes development of primary biliary cirrhosis BMC Gastroenterol 11 2011 95
82. Y. Liang, Z. Yang, and R. Zhong Smoking, family history and urinary tract infection are associated with primary biliary cirrhosis: a meta-Analysis Hepatol Res 41 2011 572 578
83. G. Mells, G. Pells, J.L. Newton, M. Heneghan, J.M. Neuberger, and D. Day The impact of primary biliary cirrhosis on perceived quality of life: the UK-PBC national study Hepatology 58 2013 273 283
84. M. Benito de Valle, M. Rahman, B. Lindkvist, E. Björnsson, R. Chapman, and E. Kalaitzakis Factors that reduce health-related quality of life in patients with primary sclerosing cholangitis Clin Gastroenterol Hepatol 10 2012 769 775
85. C. Schramm, I. Wahl, C. Weiler-Normann, K. Voigt, C. Wiegard, and C. Glaubke Health-related quality of life, depression, and anxiety in patients with autoimmune hepatitis J Hepatol 60 2014 618 624
86. E.A. Jones, and N.V. Bergasa The pruritus of cholestasis Hepatology 29 1999 1003 1004
87. U. Beuers, K.M. Boberg, O. Chazouilleres, D.E.J. Jones, P. OInvernizzi, and F. Lammert EASL practice guidelines on management of cholestatic liver diseases J Hepatol 51 2009 237 267
88. M.I. Prince, A.D. Burt, and D.E.J. Jones Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis Gut 50 2002 436 439
89. C.A. McRae, M.I. Prince, M. Hudson, C.P. Day, O.F.W. James, and D.E.J. Jones Pain as a complication of use of opiate antagonists for symptom control in cholestasis Gastroenterology 125 2003 591 596
90. A.E. Kremer, R. van Dijk, P. Leckie, F.G. Schaap, E.M.M. Kuiper, and T. Mettang Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to therapeutic interventions Hepatology 56 2012 1391 1400
91. P. Leckie, G. Tritto, R. Mookerjee, N. Davies, D.E.J. Jones, and R. Jalan "Out-patient" albumin dialysis for cholestatic patients with intractable itch Aliment Pharmacol Ther 35 2012 696 704
92. A.F. Hofmann, and P.M. Huet Nasobiliary drainage for cholestatic pruritus Hepatology 43 2006 1170 1171
93. A. Pares, M. Herrera, J. Aviles, M. Sanz, and A. Mas Treatment of resistant pruritus from cholestasis with albumin dialysis: combined analysis of patients from three centers J Hepatol 53 2010 307 312
94. J. Goldblatt, P.J.S. Taylor, T. Lipman, M. Prince, M. Baragiotta, and M.F. Bassendine The true impact of fatigue in primary biliary cirrhosis: a population study Gastroenterology 122 2002 1235 1241
95. J.L. Newton, K.G. Hollingsworth, R. Taylor, A.M. El-Sharkawy, Z.U. Khan, and R. Pearce Cognitive impairment in primary biliary cirrhosis: symptom impact and potential aetiology Hepatology 48 2008 541 549
96. E. Bjornsson, M. Simren, R. Olsson, and R.W. Chapman Fatigue in patients with primary sclerosing cholangitis Scand J Gastroenterol 39 2004 961 968
97. G. Mells, G. Pells, J.L. Newton, M. Heneghan, J.M. Neuberger, and D. Day The impact of liver transplantation on the phenotype of primary biliary cirrhosis patients in the UK-PBC cohort J Hepatol 59 1 2013 67 73
98. B. Combes Reflections on therapeutic trials in primary biliary cirrhosis Hepatology 42 2005 1009
99. M. Nakamura, A. Komori, M. Ito, H. Kondo, Y. Aiba, and K. Migita Predictive role of anti-gp210 and anticentromere antibodies in long-term outcome of primary biliary cirrhosis Hepatol Res 37 2007 S412 S419
100. M. Nakamura, H. Kondo, T. Mori, A. Komori, M. Matsuyama, and M. Ito Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis Hepatology 45 2007 118 127
101. L. Castera, J. Vergniol, J. Foucher, B. Le Bail, E. Chanteloup, and M. Haaser Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C Gastroenterology 128 2005 343 350
102. M. Friedrich-Rust, M.F. Ong, S. Martens, C. Sarrazin, J. Bojunga, and S. Zeuzem Performance of transient elastography for the staging of liver fibrosis: a meta-Analysis Gastroenterology 134 2008 960 974
103. A. Floreani, N. Cazzagon, D. Martines, L. Cavalletto, V. Baldo, and L. Chemello Performance and utility of transient elastography and noninvasive markers of liver fibrosis in primary biliary cirrhosis Dig Liver Dis 43 2011 887 892
104. M. Mayo, J. Parkes, B. Adams-Huet, B. Combes, A.S. Mills, and R.S. Markin Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay Hepatology 48 2008 1549 1557
105. C. Corpechot, F. Carrat, A. Poujol-Robert, F. Gaouar, D. Wendum, and O. Chazouilleres Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis Hepatology 56 2012 198 208
106. C. Corpechot, F. Gaouar, A. El Naggar, A. Kemgang, D. Wendum, and R. Poupon Baseline values and changes in liver stiffness measured by transient elastography are associated with severity of fibrosis and outcomes of patients with primary sclerosing cholangitis Gastroenterology 146 2014 970 979 quiz e915-e976
107. H.C. Bodenheimer, D.E.J. Jones, P. Peterson, and E. Rudell PBC management among clinicians: gaps in clinical competence and practice performance-survey findings J Hepatol 2014 S201